Cytokine-expressing Oncolytic Vaccinia Virus Western Reserve (ΔK3L), pSE-CXCL13 (CyOV-0088WQ)

This product is a CXCL13 expressing oncolytic vaccinia virus, which is based on VACV-WR with K3L deleted.CXCL13 is selectively chemotactic for B cells belonging to both the B-1 and B-2 subsets, and elicits its effects by interacting with chemokine receptor CXCR5. The deletion of K3L and CXCL13 expression could enhance the immune activity. This product can be used in oncolytic virotherapy research and vaccinie application.

Specifications
Family Poxviridae
Species Vaccinia virus
Serotype Western Reserve
Backbone VACV-WR(ΔK3L)
Backbone Background VACV-WR strain derived from Wyeth through passaging in mice and shown high tumor selectivity and strong oncolytic effect in mouse models.The engineered VACV-WR could further enhance the immune activity and the efficacy of cancer therapies.
Gene Modification ΔK3L
Promoter pSE
Transgene CXCL13
Type of Transgene Cytokine
Related Target/Protein C-X-C motif chemokine ligand 13
Capsid Modification None
Titer >1*10^8 PFU
Related Diseases Mammary tumor
Transgene
Alternative Names BLC; BCA1; ANGIE; BCA-1; BLR1L; ANGIE2; SCYB13
Gene ID 10563
Information
Introduction B lymphocyte chemoattractant, independently cloned and named Angie, is an antimicrobial peptide and CXC chemokine strongly expressed in the follicles of the spleen, lymph nodes, and Peyer's patches. It preferentially promotes the migration of B lymphocytes (compared to T cells and macrophages), apparently by stimulating calcium influx into, and chemotaxis of, cells expressing Burkitt's lymphoma receptor 1 (BLR-1). It may therefore function in the homing of B lymphocytes to follicles.
All services and products are for lab research only, not for any clinical use.

Other products

Contact Us

  • 1-631-466-5530
    44-207-097-1828
  • 1-631-207-8356

Contact Us

Copyright © 2007 - 2021 Creative Biolabs. All Rights Reserved